Heliane canepa biography of martin
This interview was conducted in November by Burt Cohen.
(Click here to access index of previous interviews.)
Q: Tell me what it was like working in the beginning days of angioplasty.
Canepa: Well, we started in a garage.
We had a show team of ten people. And, of course, there was no clean room. We made about five catheters a week. And we were not allowed to sell one catheter to a doctor who didn't show us a certificate from Andreas Gruentzig, a training certificate.
So, we had a window in this garage and we opened it. We gave the catheter and we wanted cash � Swiss francs � not U.S. dollars, no checks. And we sent the doctors back to the bank so that they could bring Swiss francs. And at that time they were very grateful, you know.
We didn't need a marketing and sales department. We didn't hold, of course, a clinical or regulatory affairs, no lot number, no batch number. There was the coffee, the cigarettes, and the cooking pot � we made the balloons in there � and we were very proud when we had five pieces of catheters.
So it was not a big thing. We never thought that we'd grow that much.
Q: You said you didn't have anyone in charge of regulatory. But you did
Canepa: Of course, it was Andreas Andreas was really a very cautious man and he had a very cautious approach to it.
Heliane Canepa President, Schneider Worldwide complete interview. Spencer B. King, III, MD Martin B. Leon, MD Course Director, Transcatheter Cardiovascular.
He trained all doctors on live cases. He was a very good educator. And he didn't allow us to sell [catheters] freely to everybody. He had absolute direct over what was going on. About all patients in every country.
Click here to access index of previous interviews. We didn't need a marketing and sales department. We didn't contain, of course, a clinical or regulatory affairs, no lot number, no batch number. So it was not a big thing.They were all reporting to him. They were all giving him the data. So he was the best clinical regulatory department we could ask for. And, of course, our top marketing department too.
Q: What was his motivation?
I think he just was a winner � a winner personality.
And very determined, very demanding. Got on our nerves sometimes.
Award-winning entrepreneur Heliane Canepa is to step down as chief executive of dental implant manufacturer Nobel Biocare. Canepa, who has been credited with building the company into the.
But fascinating. He was obsessed with his invention. And he wanted it to work. He was a very serious traits, very good-hearted, but very demanding. He just wanted things � like he wanted the prototypes, he wanted it safe. He was a very technical person, so he could talk to our engineers on a technical basis, which was very gentle , of course, because he knew materials, he knew what we were talking of.
Angioplasty / PTCA Interview - Canepa: Heliane Canepa is Former Chief Executive Officer at Nobel Biocare Holding AG. See Heliane Canepa's compensation, career history, education, & memberships.I think he was just driven by his vision to have this thing going.
Q: In the beginning, who came?
Canepa: Those were the pioneers really, because the material was awful. Today nobody would touch it anymore. It had no profile, no torquability, pushability � all those words were not known!
So there were really cardiologists coming from all countries, really the pioneering cardiologists, who believed in it.
The dynamic growth of dental implant maker Nobel Biocare is set to continue, driven by a market that is full of potential and largely untapped. The market as a whole is forecast to flourish between 18 and 20 per cent, so the firm has plenty of room for growth. Canepa told swissinfo after a presentation in Zurich on Thursday that people did not realise how dentistry had moved on. She said people did not have to be afraid of going to the dentist any more, adding that she was well aware that patients wanted to avoid pain, to limit how often they went to the dentist and to contain more long-lasting aesthetics.And there still was the fight going on against surgeons because [the cardiologists] didn't get enough patients. So in a lot of countries they couldn't even launch, because the patient was not there.
That was a real pioneering group.
And you could feel it. Innovative. I'm so glad I was part of it then because this was really something, everybodyexciting.
To start with, it's all about the dogs. How you control to be happily married for over 50 years despite having two stressful jobs and prosperous careers in different countries, and how Heliane has developed into an absolute football expert over the years. Apple Podcasts. Google Podcasts.Exciting things! It was not normal.
And the group was then growing bigger and bigger because Andreas went to Atlanta, continued to execute the courses there. And everybody was going there. He was the only one and it was a lot of playfulness.
The patients were awake, Andreas talked to them, very agreeable with the patient, you comprehend. He said "Nice belly, agreeable cook." The patient was waving after the procedure. It was this human atmosphere that you have in the beginning of such a thing, and then it's loosening up and it's getting more routine.
And patients are sedated or not part of it anymore, as in the beginning they were part of it.
Q: You mentioned the resistance against the procedure in the beginning. Does that still exist?
There is no resistance, not the resistance we had in the beginning of PTCA.
On the contrary, now we possess a program for beta radiation. And everybody wants it. Everybody wants to be on the trials. So we have much more response. People want to have something different or unused.
Award-winning entrepreneur Heliane Canepa is to step down as main person executive of dental implant manufacturer Nobel Biocare. Of course, Mr Scala will want to deposit his own focus. You possess to give him, as with every other new CEO, days before he can say where that focus lies. She was also named as the sixth most-influential female boss in Europe in by the Financial Times newspaper.So it's not favor in the beginning.
Q: What about the future of angioplasty?
There is a lot to do, still to do. Carotids, neuroradiology, aortic aneurysm, these are all places we have to do a lot of things. So I don't think it will ever end.
There will be always a place to go with ideas. It's a fascinating, absolutely fascinating industry!
Back to current "Featured Interview"
Go to Interview Index
Home � PatientCenter
send comments & suggestions to "info at angioplasty dot org"
Read our Privacy statement.
is an editorially independent informational health site
which has received unrestricted educational grants from
Medtronic plc, TCROSS NEWS, Toshiba America Medical Systems, Volcano Corporation, Terumo Medical Corporation
Cardium Therapeutics, Inc.
and Lenox Hill Heart and Vascular Institute of NY
For more information, see About Us
All content, including text, photos and video
© Venture Digital LLC